| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 21, 2018 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| May 23, 2018 | SVP/GM, Vascular Access | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 827 | $20.37 | 14,497 | |
| Apr 24, 2018 | SVP and General Counsel | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 1,280 | $19.76 | 33,172 | |
| Jan 31, 2018 | SVP/GM, Global Vascular | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 1,056 | $17.41 | 12,683 | |
| Nov 21, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | $13.53 | 69,576 | |
| Nov 21, 2017 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,873 | $17.42 | 58,703 | |
| Nov 21, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | $10.63 | 30,754 | |
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,409 | $11.92 | 48,163 | |
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Open market or private sale of non-derivative or derivative security | 27,409 | $16.29 | 20,754 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.